Insights

Innovative Science Focus NOVOS specializes in scientifically validated nutraceuticals aimed at longevity, providing an innovative product line that appeals to health-conscious consumers seeking science-backed solutions for aging. This focus on cutting-edge research positions the company to attract premium customer segments interested in advanced health supplements.

Strong Academic Collaborations With advisory boards comprising top-tier scientists from prestigious institutions like Harvard, MIT, and Salk, NOVOS demonstrates credibility and authority in the longevity space, enhancing opportunities for partnerships, sponsorships, and dissemination of co-branded scientific content.

Growing Revenue and Funding With revenue in the range of 1 to 10 million dollars and securing 3.2 million dollars in funding, NOVOS presents a promising sales opportunity for partners interested in emerging biotech brands with significant growth potential and a focus on longevity market expansion.

Purpose-Driven Brand As a Public Benefit Corporation donating profits to longevity nonprofits, NOVOS appeals to socially responsible consumers and corporate partners aligned with health and aging advocacy, creating avenues for impactful collaborations and community engagement initiatives.

Market Niche and Competitor Landscape Operating in a niche with competitors like CogniFit and Peak, NOVOS can leverage its scientific rigor and educational content to differentiate itself, offering potential sales opportunities in health and wellness markets targeting longevity, cognitive health, and personalized aging solutions.

Similar companies to NOVOS

NOVOS Tech Stack

NOVOS uses 8 technology products and services including Microsoft Advertising, TrackJS, MySQL, and more. Explore NOVOS's tech stack below.

  • Microsoft Advertising
    Advertising
  • TrackJS
    Analytics
  • MySQL
    Database
  • Swiper
    Javascript Libraries
  • Underscore.js
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Mautic
    Marketing Automation
  • Tailwind CSS
    UI Frameworks

Media & News

NOVOS's Email Address Formats

NOVOS uses at least 1 format(s):
NOVOS Email FormatsExamplePercentage
First@novoslabs.comJohn@novoslabs.com
48%
FirstL@novoslabs.comJohnD@novoslabs.com
2%
First@novoslabs.comJohn@novoslabs.com
48%
FirstL@novoslabs.comJohnD@novoslabs.com
2%

Frequently Asked Questions

Where is NOVOS's headquarters located?

Minus sign iconPlus sign icon
NOVOS's main headquarters is located at New York, New York 10017 United States. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is NOVOS's stock symbol?

Minus sign iconPlus sign icon
NOVOS is a publicly traded company; the company's stock symbol is 688052.SS.

What is NOVOS's official website and social media links?

Minus sign iconPlus sign icon
NOVOS's official website is novoslabs.com and has social profiles on LinkedInCrunchbase.

What is NOVOS's SIC code NAICS code?

Minus sign iconPlus sign icon
NOVOS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NOVOS have currently?

Minus sign iconPlus sign icon
As of March 2026, NOVOS has approximately 32 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Founder, Ceo: C. M.Director Of Digital Innovation & Growth: N. S.Marketing Director: I. A.. Explore NOVOS's employee directory with LeadIQ.

What industry does NOVOS belong to?

Minus sign iconPlus sign icon
NOVOS operates in the Biotechnology Research industry.

What technology does NOVOS use?

Minus sign iconPlus sign icon
NOVOS's tech stack includes Microsoft AdvertisingTrackJSMySQLSwiperUnderscore.jsjQueryMauticTailwind CSS.

What is NOVOS's email format?

Minus sign iconPlus sign icon
NOVOS's email format typically follows the pattern of First@novoslabs.com. Find more NOVOS email formats with LeadIQ.

How much funding has NOVOS raised to date?

Minus sign iconPlus sign icon
As of March 2026, NOVOS has raised $3.2M in funding. The last funding round occurred on Oct 01, 2021 for $3.2M.

When was NOVOS founded?

Minus sign iconPlus sign icon
NOVOS was founded in 2018.

NOVOS

Biotechnology ResearchNew York, United States11-50 Employees

NOVOS leverages science and data to create the best nutraceuticals to extend human lifespan.

We at NOVOS believe much more can be done to slow down aging through science, so we create the first supplements in the world that are:

• Based on the best available science
• Created with the world’s top experts in the aging field 
• Use scientifically validated ingredients that extend lifespan in various organisms
• Focused on the 12 mechanisms of aging mechanisms to leverage synergistic effects 
• Include ingredients shown to have beneficial effects on aging in humans

The result is NOVOS, the best longevity supplements available.

NOVOS’ scientific advisors are biochemists, geneticists and professors from Harvard, MIT, University of Liverpool, University of Washington, Salk Institute, and other universities & institutes around the world. 

Our scientists have received honors that include Breakthroughs in Gerontology Award, an Alzheimer’s Association New Investigator Award, and an Ellison Medical Foundation New Scholar in Aging Award. 

Each one of them is a pioneer in the longevity field and have been featured by 60 Minutes, TIME magazine, BBC, CNN, Science, Scientific American, Washington Post, New York Times, and countless other publications.

NOVOS is a Public Benefit Corporation (PBC). A portion of our profits and equity is donated to nonprofits in the longevity science space, like the 501(c)(3), Life Extension Advocacy Foundation (LEAF).

NOVOS also creates free content to educate people on how to live longer, healthier lives, even if they don’t use NOVOS, which you can find on our blog at NovosLabs.com.

Section iconCompany Overview

Headquarters
New York, New York 10017 United States
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
688052.SS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $3.2M

    NOVOS has raised a total of $3.2M of funding over 2 rounds. Their latest funding round was raised on Oct 01, 2021 in the amount of $3.2M.

  • $1M$10M

    NOVOS's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $3.2M

    NOVOS has raised a total of $3.2M of funding over 2 rounds. Their latest funding round was raised on Oct 01, 2021 in the amount of $3.2M.

  • $1M$10M

    NOVOS's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.